Quote | Immuneering Corporation (NASDAQ:IMRX)
Last: | $1.13 |
---|---|
Change Percent: | 3.67% |
Open: | $1.1 |
Close: | $1.09 |
High: | $1.15 |
Low: | $1.09 |
Volume: | 16,212 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Immuneering Corporation (NASDAQ:IMRX)
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies...
2024-05-08 10:50:01 ET More on Immuneering Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone Seeking Alpha's Quant Rating on Immuneering Historical earnings data for Immuneering Read the full article on Seeking Alpha For f...
Message Board Posts | Immuneering Corporation (NASDAQ:IMRX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Immuneering Corporation Company Name:
IMRX Stock Symbol:
NASDAQ Market:
Immuneering Corporation Website:
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies...
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - ...
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of...